Literature DB >> 7044591

VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity.

J D Loike.   

Abstract

VP16-213, a semi-synthetic derivative of podophyllotoxin, is an effective antitumor agent in the treatment of a variety of leukemias and solid tumors. A comparison of the mechanism of action of VP16-213 and podophyllotoxin has revealed that although both drugs inhibit the uptake of nucleosides into HeLa cells, they exhibit other biological properties which are quite distinct. Podophyllotoxin is a potent inhibitor of microtubule assembly in vitro, while VP16-213 has no effect in this system. VP16-213 induces single stranded breaks in HeLa cells DNA, an effect which may be related to its antitumor activity. In contrast to VP16-213 treated cells, podophyllotoxin-treated cells maintain DNA integrity. Structure-activity relationship studies have identified some of chemical sites of VP16-213 and podophyllotoxin responsible for each of their biological properties. These studies illustrate that chemical modification of podophyllotoxin can generate derivatives which possess new and unique biological properties.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7044591     DOI: 10.1007/bf00254530

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  44 in total

1.  Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.

Authors:  L M Allen; P J Creaven
Journal:  Eur J Cancer       Date:  1975-10       Impact factor: 9.162

2.  Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells.

Authors:  J D Loike; S B Horwitz
Journal:  Biochemistry       Date:  1976-12-14       Impact factor: 3.162

3.  VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

Authors:  F Cavalli; R W Sonntag; F Jungi; H J Senn; K W Brunner
Journal:  Cancer Treat Rep       Date:  1978-03

Review 4.  Transport of nucleosides, nucleic acid bases, choline and glucose by animal cells in culture.

Authors:  P G Plagemann; D P Richey
Journal:  Biochim Biophys Acta       Date:  1974-12-16

5.  Structure of the mitotic spindle inhibitor colcemid. N-desacetyl-N-methylcolchicine.

Authors:  T N Margulis
Journal:  J Am Chem Soc       Date:  1974-02-06       Impact factor: 15.419

6.  The effect of podophyllin cytostatics SP-I and SP-G on the proliferation and respiration of HeLa cells in vitro.

Authors:  F Svec; J Kovarík
Journal:  Neoplasma       Date:  1968       Impact factor: 2.575

7.  Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners.

Authors:  J D Loike; C F Brewer; H Sternlicht; W J Gensler; S B Horwitz
Journal:  Cancer Res       Date:  1978-09       Impact factor: 12.701

8.  Opposite end assembly and disassembly of microtubules at steady state in vitro.

Authors:  R L Margolis; L Wilson
Journal:  Cell       Date:  1978-01       Impact factor: 41.582

Review 9.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

10.  Kinetic and steady-state analysis of microtubules in the presence of colchicine.

Authors:  W J Deery; R C Weisenberg
Journal:  Biochemistry       Date:  1981-04-14       Impact factor: 3.162

View more
  10 in total

1.  Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients.

Authors:  C Rossi; M Zucchetti; C Sessa; R Urso; C Mangioni; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 2.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

3.  Cytotoxic properties of a new synthetic demethylpodophyllotoxin derivative, BN 58705, against human tumor cell lines.

Authors:  H Morimoto; P Principe; J P Robin; C Broquet; J M Mencia-Huerta; P Braquet; B Bonavida
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.

Authors:  Ryan P Bender; Michael J Jablonksy; Mohammad Shadid; Ian Romaine; Norma Dunlap; Clemens Anklin; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2008-03-21       Impact factor: 3.162

Review 5.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma.

Authors:  E Erba; P Ubezio; T Colombo; M Broggini; L Torti; M Vaghi; M D'Incalci; L Morasca
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 7.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

8.  Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme.

Authors:  Amy M Wilstermann; Ryan P Bender; Murrell Godfrey; Sungjo Choi; Clemens Anklin; David B Berkowitz; Neil Osheroff; David E Graves
Journal:  Biochemistry       Date:  2007-06-20       Impact factor: 3.162

Review 9.  Podophyllotoxin: a novel potential natural anticancer agent.

Authors:  Hamidreza Ardalani; Amir Avan; Majid Ghayour-Mobarhan
Journal:  Avicenna J Phytomed       Date:  2017 Jul-Aug

Review 10.  Broken by the Cut: A Journey into the Role of Topoisomerase II in DNA Fragility.

Authors:  Naomi D Atkin; Heather M Raimer; Yuh-Hwa Wang
Journal:  Genes (Basel)       Date:  2019-10-12       Impact factor: 4.141

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.